Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC By Ogkologos - March 17, 2025 371 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Serplulimab Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR Prostate Cancer Genomics in Racial Minority Groups February 18, 2021 Occurrence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan in Patients... May 8, 2021 Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer January 3, 2024 FDA Approval of KRAS Inhibitor Sotorasib for Lung Cancer Hailed as... June 25, 2021 Load more HOT NEWS New on NCI’s Websites for December 2023 24-Year-Old Woman with Terminal Breast Cancer Dreams of Fairytale Wedding with... Belzutifan Approved to Treat Tumors Linked to Inherited Disorder VHL Mutation Screening Could Reveal Whether Hormone Treatment Will Work for Breast...
